Navigation Links
QualTech Laboratories Validates USP Protocols for Anti-Factor IIa Chromogenic Assay for Potency
Date:8/12/2009

OCEAN, N.J., Aug. 12 /PRNewswire/ -- QualTech Laboratories, Inc., an analytical testing laboratory specializing in biological assays, toxicity studies, and quality control measures, announced today that they have validated the USP (United States Pharmacopeia) method for the anti-factor IIa chromogenic assay for potency. This anti-factor IIa assay is a required component of the newly-revised Heparin Sodium monograph, which becomes effective October 1, 2009.

The Heparin Sodium monograph was revised due to previous contamination which resulted in multiple fatalities. The revisions to the Heparin Sodium monograph improve purity, potency, and identity tests. Among these revisions, the anti-factor IIa assay for potency replaces the previously-used sheep plasma-based clotting assay.

In anticipation of the changes to the Heparin Sodium monograph, QualTech Laboratories began testing the new anti-factor IIa assay protocols in early 2009, and validated the method in March of 2009. Elizabeth Raike, President and CEO of QualTech Laboratories, affirms, "We have validated the anti-factor IIa chromogenic assay according to USP <1225> Validation of Compendial Procedures for accuracy, precision, specificity, linearity, and range. We wanted to be proactive in validating the anti-factor IIa assay so that we could help companies smoothly transition to the requirements of the revised USP Heparin Sodium monograph."

QualTech Laboratories has been performing the anti-factor IIa assay for years according to both EP (European Pharmacopoeia) and BP (British Pharmacopoeia) methods, and therefore offers a wealth of experience to pharmaceutical firms. Additionally, the anti-factor Xa
'/>"/>

SOURCE QualTech Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
6. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
7. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ ... its CytoSorb® extracorporeal cytokine adsorber to reduce deadly ... the receipt of $385,642, net of transaction costs, ... the Technology Business Tax Certificate Transfer Program sponsored ...
(Date:1/23/2015)... 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... development and sale of patented biopharmaceutical medicine, modernized traditional ... (API) today announced the business and development progress at ... 1. Following the September 2014 JCM application (No. 51268) ...
(Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... years since the release of their debut recording Love is King, ... & Matthew Love – the duo are pleased to announce their ... Swan Records on February 24, 2015. , THE ROAD offers the ... all of us to walk out of the mire of our ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... Assurant, Inc. ("Assurant"),(NYSE: AIZ ), a premier ... announced today that Jane Meyer,has been appointed senior ... appointed senior vice president, organizational development and,corporate communications ... Ms. Meyer and Mr. Walker will continue to ...
... hearing loss might think they are saving significantly more ... likely will be disappointed or could be taking ... research. , Professor Jerry Punch of the Department ... a lifelong education alumna and international student from Denmark, ...
... Learning Resources to Help ... Alleviate Nursing Shortage, INDIANAPOLIS, Aug. 13 ... nursing program in the city of,Glendale, California, in conjunction with the ... This is the,second program of its kind from Orbis, with the ...
... August 13, 2008 Relational Uncertainty refers to ... relationship involvement. A new study in the journal ... uncertainty and found that fluctuations in perceptions of ... , Denise Haunani Solomon of Pennsylvania State ...
... 13 Experts on health care,information technology ... transparency,improving outcomes and patient safety, HIT applications, ... Informatics Symposium to be,held September 8-10, 2008, ... American College of Physicians; John Glaser, PhD, ...
... hospitals in West Allis, Green Bay and Two Rivers ... Top Hospitals(R) Performance Improvement Leaders, MILWAUKEE, Aug. 13 ... hospitals identified by Thomson Reuter as having,demonstrated the fastest, ... Allis Medical Center and Aurora BayCare Medical Center of,Green ...
Cached Medicine News:Health News:Assurant Announces Two Executive Appointments 2Health News:Study finds not all hearing aids are created equal 2Health News:Orbis Education Expands Nursing Education Program to Glendale, California 2Health News:Orbis Education Expands Nursing Education Program to Glendale, California 3Health News:Three Aurora Hospitals Named Top Performers in National Thomson Reuters Annual Survey 2Health News:Three Aurora Hospitals Named Top Performers in National Thomson Reuters Annual Survey 3
Digital Ultrasonic Diagnostic Imaging System...
...
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Medicine Products: